Expertise in
12
conditions

Dr. Sukeshi P. Arora

University Of Texas Health Science Center At San Antonio
San Antonio, TX
Expertise in
12
conditions
Specialties:Oncology | Hematology | Hematology Oncology
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
OverviewInsuranceLocationsClinical Research

Overview

Sukeshi Arora is an Oncologist and a Hematologist in San Antonio, Texas. Dr. Arora is highly rated in 12 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Familial Pancreatic Cancer. Dr. Arora is currently accepting new patients.

Her clinical research consists of co-authoring 31 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
University Health System
Languages Spoken
English
Hindi
Spanish
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
7703 Floyd Curl Dr, Suite Mc7977, San Antonio, TX 78229
210-450-9000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
Enrollment Status: Completed
Publish Date: May 01, 2024
Intervention Type: Other, Dietary supplement
Study Phase: Phase 2
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Enrollment Status: Terminated
Publish Date: April 12, 2022
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

31 Total Publications

Meta-analysis of randomized controlled trials of external-beam radiation versus transarterial chemoembolization for hepatocellular carcinoma.
Meta-analysis of randomized controlled trials of external-beam radiation versus transarterial chemoembolization for hepatocellular carcinoma.
Journal: Cancer
Published: September 26, 2024
Similar Doctors
Expertise in
21
conditions
Dr. Montaser F. Shaheen
Hematology | Hematology Oncology | Oncology
Expertise in
21
conditions
Dr. Montaser F. Shaheen
Hematology | Hematology Oncology | Oncology

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (0.5 mi)
210-450-9000
Languages Spoken:
English, Arabic, Faroese, Farsi
See accepted insurances
Accepting New Patients

Montaser Shaheen is a Hematologist and a Hematologist Oncology provider in San Antonio, Texas. Dr. Shaheen is highly rated in 21 conditions, according to our data. His top areas of expertise are Melanoma, Neuroendocrine Tumor, Adult Soft Tissue Sarcoma, and Undifferentiated Pleomorphic Sarcoma. Dr. Shaheen is currently accepting new patients.

Expertise in
17
conditions
Dr. Paul J. Shaughnessy
Hematology Oncology | Oncology | Hematology
Expertise in
17
conditions
Dr. Paul J. Shaughnessy
Hematology Oncology | Oncology | Hematology

Methodist Physician Practices PLLC

7700 Floyd Curl Dr, 
San Antonio, TX 
 (0.3 mi)
210-575-4000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Paul Shaughnessy is a Hematologist Oncology specialist and an Oncologist in San Antonio, Texas. Dr. Shaughnessy is highly rated in 17 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Shaughnessy is currently accepting new patients.

Expertise in
19
conditions
Dr. Ildefonso I. Rodriguez-Rivera
Hematology Oncology | Hematology | Oncology
Expertise in
19
conditions
Dr. Ildefonso I. Rodriguez-Rivera
Hematology Oncology | Hematology | Oncology

Texas Oncology PA

2829 Babcock Rd, Suite 300, 
San Antonio, TX 
 (1.0 mi)
210-580-9544
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ildefonso Rodriguez-Rivera is a Hematologist Oncology specialist and a Hematologist in San Antonio, Texas. Dr. Rodriguez-Rivera is highly rated in 19 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Gastric Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Large-Cell Immunoblastic Lymphoma. Dr. Rodriguez-Rivera is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile